| Company Name: |
YantaiBio |
| Tel: |
13758194781; 13758194781 |
| Email: |
764619768@qq.com |
|
| | NBI 6024 Basic information |
| Product Name: | NBI 6024 | | Synonyms: | NBI 6024;Glycine, L-seryl-L-histidyl-L-leucyl-L-valyl-L-alpha-glutamyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-L-valyl-L-alanylglycyl-L-alpha-glutamyl-L-arginyl- | | CAS: | 239480-61-6 | | MF: | C66H112N20O21 | | MW: | 1521.73 | | EINECS: | | | Product Categories: | | | Mol File: | 239480-61-6.mol |  |
| | NBI 6024 Chemical Properties |
| | NBI 6024 Usage And Synthesis |
| Uses | NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients[1][2]. | | in vivo | NBI-6024 (0.005-20 mg/kg, s.c.) delays the onset and reduces the incidence of diabetes in mice[2].
| Animal Model: | Nonobese diabetic (NOD) mice[2] | | Dosage: | 0.005, 0.05, 0.5, 5, 10, 20 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice). |
| | References | [1] D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. DOI:10.1111/j.1365-3083.2005.01705.x
[2] Alleva DG, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. DOI:10.2337/diabetes.51.7.2126 |
| | NBI 6024 Preparation Products And Raw materials |
|